-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QEj59edGUum8aPHMqEKnMv0rz3kMV/QeqvMudzIp1RsSMLsEsBLIM8WsXW4zUbVq RqaX/DQbgBxqtqQarSZwJA== 0000927016-00-001364.txt : 20000418 0000927016-00-001364.hdr.sgml : 20000418 ACCESSION NUMBER: 0000927016-00-001364 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20000413 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 20000417 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CURAGEN CORP CENTRAL INDEX KEY: 0001030653 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 061331400 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-23223 FILM NUMBER: 603064 BUSINESS ADDRESS: STREET 1: 555 LONG WHARF DRIVE STREET 2: 11TH FL CITY: NEW HAVEN STATE: CT ZIP: 06511 8-K 1 FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ______________ Date of Report (Date of earliest event reported): April 13, 2000 CuraGen Corporation (Exact name of registrant as specified in its charter) Delaware 0-23223 06-1331400 - ------------------ --------------------- --------------------- (State or other (Commission (IRS Employer jurisdiction of File Number) Identification No.) incorporation) 555 Long Wharf Drive, 11th Floor New Haven, Connecticut 06511 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (203) 401-3330 ------------------------------ Page 1 of 6 pages ITEM 5. OTHER EVENTS. On April 13, 2000, CuraGen Corporation announced the renewal of its drug research collaboration with Genentech, Inc. for a minimum of an additional two and one-half years. The collaboration, which began in 1997, involves the application of CuraGen's high-throughput functional genomic technologies and disease expertise to advance the discovery of novel protein therapeutics and antibodies. The information contained in such press release is incorporated herein by reference and filed as Exhibit 99.1 hereto. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS. (c) Exhibits. 99.1 The Registrant's Press Release dated April 13, 2000. Page 2 of 6 pages SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CURAGEN CORPORATION (Registrant) Date: April 14, 2000 By: /s/ Jonathan M. Rothberg ------------------------- Chief Executive Officer, Chairman of the Board of Directors and President Page 3 of 6 pages EXHIBIT INDEX ------------- Exhibit Sequential Number Description Page Number - ------- ----------- ----------- 99.1 The Registrant's Press Release 5 dated April 13, 2000. Page 4 of 6 pages EX-99.1 2 PRESS RELEASE DATED APRIL 13, 2000 Exhibit 99.1 Press Release of the Registrant CURAGEN AND GENENTECH EXTEND BROAD-BASED DRUG DISCOVERY COLLABORATION CURAGEN RECEIVES PAYMENT TO REVISE AND EXTEND COLLABORATION AGREEMENT Contact: - --------- Mark R. Vincent - --------------- Director, Corporate Communications mvincent@curagen.com CuraGen Corporation 1-888-GENOMICS www.curagen.com NEW HAVEN, CT AND SAN FRANCISCO, CA - APRIL 13, 2000 - CuraGen Corporation (Nasdaq: CRGN), an integrated genomics based drug discovery and development company, and Genentech, Inc. (NYSE: DNA), today announced the renewal of their drug research collaboration for a minimum of an additional two and one-half years. The collaboration, which began in 1997, involves the application of CuraGen's high-throughput functional genomic technologies and disease expertise to advance the discovery of novel protein therapeutics and antibodies. CuraGen will receive research funding payments from Genentech for the collaborative discovery of genes that represent potential drugs, drug targets, and clinical markers. Under the terms of this extension, Genentech will pay CuraGen research fees for access to CuraGen's functional genomic technologies and databases. In return, Genentech will retain the rights to license, develop, and market therapeutics derived from these research efforts. CuraGen will also receive milestone and royalty payments based upon the development and sales of products that result from this collaboration. Financial terms of this deal were not disclosed. "We are optimistic about the potential of this collaboration and are looking forward to making additional significant progress in our joint drug discovery efforts," said Dennis J. Henner, Ph.D., Senior Vice President of Research for Genentech, Inc. "We are excited by this expansion and by the opportunity to continue advancing our achievements with Genentech. Since the inception of this collaboration, CuraGen has delivered a number of genes and potential protein drug and drug target candidates that may lead to new therapeutics," stated Jonathan M. Rothberg, Ph.D., Founder, Chairman, and CEO of CuraGen Corporation. Recent publications highlighting results of this collaboration include a manuscript outlining the discovery of a murine chemokine that regulates the proliferation of red blood cells, which appeared in the February edition of the journal Immunity. A second manuscript was published in the April edition of The Journal of Biological Chemistry that discusses discoveries made surrounding the hormone leptin and its role in obesity. Genentech is the second partner to expand its collaboration with CuraGen this year. In March, COR Therapeutics expanded its agreement with CuraGen to utilize CuraGen's PathCalling(TM) proteomics technology and bioinformatics systems to create an annotated database of protein-protein interactions within disease pathways, which are derived from cardiovascular endothelial cells. About Genentech, Inc. Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Thirteen of the approved products of biotechnology stem from Genentech science. Genentech markets seven products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA. About CuraGen Corporation CuraGen Corporation is advancing the discovery and development of pharmaceutical and life science products through the systematic application of genomics. CuraGen's fully integrated, Internet-based functional genomic technologies, services, and information systems are designed to rapidly generate comprehensive information about genes, human genetic variations, gene expression, protein pathways, and potential products that affect these pathways. The Company is applying these functional genomic technologies to develop protein drugs, antibody drugs, and small molecule drug targets. CuraGen's research collaborators include Abgenix, Biogen, COR Therapeutics, Gemini, Genentech, Glaxo Wellcome, Hoffmann-La Roche, Pioneer Hi-Bred International, and Roche Vitamins. CuraGen employs over 300 people and is headquartered in New Haven, CT. Additional Company information is available at http://www.curagen.com. Page 5 of 6 pages This release may contain forward-looking statements that are subject to certain risks and uncertainties, including CuraGen's ability to successfully enhance and develop its technologies. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. The Company cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: the Company's early stage of development, technological uncertainty and product development risks, uncertainty of additional funding, reliance on research collaborations, competition, the Company's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights. Page 6 of 6 pages -----END PRIVACY-ENHANCED MESSAGE-----